Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells.
about
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationSquamous cell lung cancer: from tumor genomics to cancer therapeuticsA place for precision medicine in bladder cancer: targeting the FGFRs.Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398.Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cellsAdvances and challenges in targeting FGFR signalling in cancer.Fibroblast growth factor-mediated crosstalk in cancer etiology and treatment.Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers.The integration of genomics testing and functional proteomics in the era of personalized medicine.RAS-MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade.
P2860
Q28079309-3163FB22-B927-4E92-AE1F-479DAB96349BQ28086951-611D8A8E-FCE4-4963-BDE7-26BAB78B62AAQ30249143-1284A056-E634-4FB4-ACA2-3276E90D3723Q34525925-8870F8F8-973E-4106-AF23-4B4B9A74E744Q36983860-5BB57AD0-15B0-42E3-B887-1EDCBDE92BE3Q37628912-764FAF0C-43A2-4DED-8845-384B643E43B6Q38714068-D6B873FA-A27F-4AFC-B5B9-201390882F95Q38939465-40067682-8330-4169-93EA-224A885E2521Q39183442-25E27FF0-1BEF-43BC-9A87-006A9612FC4DQ39282670-51D9EE74-9776-4997-B115-496D9F1930A2Q40343596-A40643F3-DF7C-4CB5-8A9F-15E20561C440Q47671139-F0F12CCB-F7EB-4C18-8869-2F09BD667383Q49791794-0C4CE119-BED5-4A43-96F3-E9BBBB3B9E57Q50078274-47A78F75-5976-4947-B145-172B7BDA64F3Q52589214-372319B9-1988-4C28-8B37-70B4DF2523C0
P2860
Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Ligand-associated ERBB2/3 acti ...... FGFR3-dependent cancer cells.
@en
type
label
Ligand-associated ERBB2/3 acti ...... FGFR3-dependent cancer cells.
@en
prefLabel
Ligand-associated ERBB2/3 acti ...... FGFR3-dependent cancer cells.
@en
P2093
P2860
P356
P1433
P1476
Ligand-associated ERBB2/3 acti ...... FGFR3-dependent cancer cells.
@en
P2093
P S Hammerman
P2860
P2888
P304
P356
10.1038/ONC.2014.161
P407
P577
2014-06-09T00:00:00Z
P5875
P6179
1005706304